OBJCTIVE: To study the clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor (cPNET), as well as the risks factors for poor prognosis. METHODS: A retrospective analysis was performed for the clinical data of 42 children who were diagnosed with cPNET from June 2012 to September 2018. RESULTS: The 42 children had a median overall survival (OS) time of 2.0 years and a median event-free survival (EFS) time of 1.3 years; the 1-, 3-, and 5-year OS rates were 76.2%±6.6%, 41.4%±8.7%, 37.3%±8.8% respectively, and the 1-, 3-, and 5-year EFS rates were 64.3%±7.4%, 32.7%±8.0%, 28.0%±8.1% respectively. The univariate analysis showed that there were significant differences in the OS and EFS rates among the children with different patterns of surgical resection, chemotherapy cycles, and risk grades (P<0.05), and there was also a significant difference in the OS rate between the children receiving radiotherapy and those not receiving radiotherapy (P<0.05). The multivariate Cox regression analysis showed that chemotherapy cycles and risk grade were independent influencing factors for EFS and OS rates (P<0.05). The EFS and OS rates increased with the increase in chemotherapy cycles and the reduction in risk grade. CONCLUSIONS: Multimodality therapy with surgery, chemotherapy, and radiotherapy is an effective method for the treatment of cPNET in children. Early diagnosis and treatment and adherence to chemotherapy for as long as possible may improve EFS and OS rates.
OBJCTIVE: To study the clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor (cPNET), as well as the risks factors for poor prognosis. METHODS: A retrospective analysis was performed for the clinical data of 42 children who were diagnosed with cPNET from June 2012 to September 2018. RESULTS: The 42 children had a median overall survival (OS) time of 2.0 years and a median event-free survival (EFS) time of 1.3 years; the 1-, 3-, and 5-year OS rates were 76.2%±6.6%, 41.4%±8.7%, 37.3%±8.8% respectively, and the 1-, 3-, and 5-year EFS rates were 64.3%±7.4%, 32.7%±8.0%, 28.0%±8.1% respectively. The univariate analysis showed that there were significant differences in the OS and EFS rates among the children with different patterns of surgical resection, chemotherapy cycles, and risk grades (P<0.05), and there was also a significant difference in the OS rate between the children receiving radiotherapy and those not receiving radiotherapy (P<0.05). The multivariate Cox regression analysis showed that chemotherapy cycles and risk grade were independent influencing factors for EFS and OS rates (P<0.05). The EFS and OS rates increased with the increase in chemotherapy cycles and the reduction in risk grade. CONCLUSIONS: Multimodality therapy with surgery, chemotherapy, and radiotherapy is an effective method for the treatment of cPNET in children. Early diagnosis and treatment and adherence to chemotherapy for as long as possible may improve EFS and OS rates.
Authors: Fernando Carceller; Francisco Bautista; Irene Jiménez; Raquel Hladun-Álvaro; Cécile Giraud; Luca Bergamaschi; Madhumita Dandapani; Isabelle Aerts; François Doz; Didier Frappaz; Michela Casanova; Bruce Morland; Darren R Hargrave; Gilles Vassal; Andrew D J Pearson; Birgit Geoerger; Lucas Moreno; Lynley V Marshall Journal: J Neurooncol Date: 2017-12-13 Impact factor: 4.130
Authors: Carsten Friedrich; Monika Warmuth-Metz; André O von Bueren; Johannes Nowak; Brigitte Bison; Katja von Hoff; Torsten Pietsch; Rolf D Kortmann; Stefan Rutkowski Journal: J Neurosurg Pediatr Date: 2015-01-02 Impact factor: 2.375
Authors: Fernando Carceller; Francisco J Bautista; Irene Jiménez; Raquel Hladun-Álvaro; Cécile Giraud; Luca Bergamaschi; Madhumita Dandapani; Isabelle Aerts; François Doz; Didier Frappaz; Michela Casanova; Bruce Morland; Darren R Hargrave; Lynley V Marshall; Gilles Vassal; Andrew D J Pearson; Birgit Geoerger; Lucas Moreno Journal: Eur J Cancer Date: 2016-09-21 Impact factor: 9.162
Authors: Stefan Rutkowski; Udo Bode; Frank Deinlein; Holger Ottensmeier; Monika Warmuth-Metz; Niels Soerensen; Norbert Graf; Angela Emser; Torsten Pietsch; Johannes E A Wolff; Rolf D Kortmann; Joachim Kuehl Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Murali Chintagumpala; Tim Hassall; Shawna Palmer; David Ashley; Dana Wallace; Kimberly Kasow; Thomas E Merchant; Matthew J Krasin; Robert Dauser; Frederick Boop; Robert Krance; Shiao Woo; Robyn Cheuk; Ching Lau; Richard Gilbertson; Amar Gajjar Journal: Neuro Oncol Date: 2008-09-16 Impact factor: 12.300
Authors: Teresa de Rojas; Francisco Bautista; Miguel Flores; Lucía Igual; Raquel Rubio; Eduardo Bardón; Lucía Navarro; Laura Murillo; Raquel Hladun; Adela Cañete; Miguel Garcia-Ariza; Carmen Garrido; Ana Fernández-Teijeiro; Eduardo Quiroga; Carlota Calvo; Anna Llort; Inmaculada de Prada; Luis Madero; Ofelia Cruz; Lucas Moreno Journal: J Neurooncol Date: 2017-12-16 Impact factor: 4.130